Recent News

• 02.04.2026 - AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• 02.03.2026 - Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
• 02.03.2026 - AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
• 01.29.2026 - AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
• 01.28.2026 - Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
• 01.16.2026 - AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
• 01.12.2026 - AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
• 01.12.2026 - AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
• 01.12.2026 - AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
• 01.07.2026 - AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Recent Filings